According to a new report by Polaris Market Research, the global theranostics market was valued at USD 2.36 billion in 2025 and is projected to reach USD 8.67 billion by 2034, expanding at a CAGR of 15.5% over the forecast period. Growth is underpinned by rising demand for personalized medicine, expanding molecular diagnostics adoption, and accelerating integration of AI and companion diagnostics across key end-use industries.

What Is Driving Theranostics Market Growth?

Demand is climbing as advancements in personalized medicine converge with rising adoption of molecular diagnostics and companion diagnostics. Manufacturers and end users are prioritizing biomarker-driven treatment selection, pushing theranostics adoption across oncology, neurology, and cardiology. Polaris analysts note that the growing integration of AI and data analytics into diagnostic workflows positions the segment for sustained double-digit growth through 2034, with oncology emerging as the largest revenue contributor and neurology posting the fastest incremental gains.

Key Trends Shaping the Theranostics Industry

AI-Enabled Diagnostic and Treatment Planning

Artificial intelligence and data analytics are increasingly used to interpret molecular imaging and genomic profiles, enhancing diagnostic accuracy, treatment planning, and real-time disease monitoring across theranostic applications.

Expansion of Companion Diagnostics

Technological innovations in companion diagnostics are helping ensure the right patient receives the right therapy, with rising approvals of targeted therapies in oncology closely tied to companion diagnostic development.

Growth in Radiotheranostics and Molecular Imaging

Rising use of radiopharmaceuticals, particularly in prostate and neuroendocrine cancers, alongside advancing PET and SPECT imaging, is expanding the reach of theranostics into new clinical applications.

Market Segmentation: Breaking Down the Theranostics Market

Polaris segments the theranostics market by product type, application, technology, end user, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Product Type

The reagents segment led the market in 2025, accounting for 47.9% of revenue, given the critical role reagents play in biomarker assays and molecular diagnostic testing. The software segment is projected to expand at the fastest CAGR of 15.4% through 2034 as data analytics and AI become central to interpreting diagnostic results and guiding treatment decisions.

By Application

Oncology remains the dominant application, holding 62.7% share in 2025 on the back of rising cancer prevalence and growing adoption of targeted therapies. Neurology is gaining share fastest, projected to grow at a 15.3% CAGR as neurodegenerative disease diagnostics and biomarker research expand.

By Technology

Genomics led the market in 2025 with a 48.3% share, driven by widespread adoption of next-generation sequencing in precision oncology. Proteomics is the fastest-growing technology segment, expanding at a 15.8% CAGR as protein-based biomarker discovery advances.

By End User

Hospitals captured the largest share in 2025 at 48.3%, reflecting their central role in integrating advanced diagnostic and therapeutic technologies into patient care. Diagnostic laboratories are the fastest-growing end-user segment, projected at a 15.9% CAGR as demand for early disease detection rises.

Regional Outlook: Where Is Theranostics Growing Fastest?

North America led the market in 2025 with a 46.2% revenue share, supported by advanced healthcare infrastructure, high adoption of precision medicine, and strong pharmaceutical and biotechnology investment. Europe followed with 28.0% share, led by Germany, the UK, and France. Asia Pacific is expected to post the fastest CAGR through 2034 at 17.0%, driven by rapid healthcare infrastructure development and rising chronic disease prevalence in China, Japan, and India.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/global-theranostics-market 

Competitive Landscape: Leading Theranostics Companies

Key players profiled in the report include Siemens Healthineers AG, GE HealthCare Technologies Inc., Lantheus Holdings, Inc., and Thermo Fisher Scientific Inc., who are focusing on molecular imaging portfolio expansion, radiopharmaceutical development, and strategic acquisitions to strengthen market position across the oncology and genomics segments outlined above. Recent moves include OncoLux Inc.'s March 2026 know-how agreement with Mayo Clinic to advance optical theranostics in robotic bronchoscopy, alongside continued expansion by Lantheus and Siemens Healthineers in radiopharmaceutical capacity.

Why It Matters for Buyers Evaluating Market Entry

For stakeholders researching the theranostics market, this report benchmarks market share, segment-level pricing, and forecast data — by product type, application, technology, end user, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking neurology and proteomics as growth adjacencies.

More Trending Latest Reports By Polaris Market Research:

Telestroke Services Market

Automotive Blind Spot Detection System Market

1-Decene Market

Pad-mounted Switchgear Market

Automotive Blind Spot Detection System Market

Solar Panels Market

Collagen Market

Navigating the Oil Storage Terminal Market: Trends and Insights for Key Players

Compressed Natural Gas (CNG) Market